What is Zacks Research’s Forecast for Allegion Q1 Earnings?

Allegion plc (NYSE:ALLE) – Investment analysts at Zacks Research raised their Q1 2025 EPS estimates for Allegion in a report issued on Tuesday, January 14th. Zacks Research analyst R. Department now forecasts that the scientific and technical instruments company will post earnings per share of $1.63 for the quarter, up from their prior estimate of $1.62. The consensus estimate for Allegion’s current full-year earnings is $7.41 per share. Zacks Research also issued estimates for Allegion’s Q3 2025 earnings at $2.02 EPS, Q4 2025 earnings at $2.07 EPS, FY2025 earnings at $7.53 EPS, Q1 2026 earnings at $1.60 EPS, Q2 2026 earnings at $1.86 EPS, Q3 2026 earnings at $1.97 EPS, Q4 2026 earnings at $1.93 EPS and FY2026 earnings at $7.36 EPS.

ALLE has been the topic of a number of other research reports. Robert W. Baird raised their target price on shares of Allegion from $145.00 to $152.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company cut their price objective on shares of Allegion from $152.00 to $140.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 7th. Morgan Stanley started coverage on Allegion in a report on Monday, January 6th. They set an “equal weight” rating and a $137.00 target price for the company. Barclays cut their price target on Allegion from $137.00 to $134.00 and set an “underweight” rating on the stock in a report on Wednesday, January 8th. Finally, Mizuho upped their price objective on Allegion from $135.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $140.83.

Allegion Stock Performance

Shares of Allegion stock opened at $131.10 on Thursday. The company has a current ratio of 1.71, a quick ratio of 1.29 and a debt-to-equity ratio of 1.26. The stock’s fifty day moving average price is $136.30 and its 200-day moving average price is $136.17. The firm has a market cap of $11.40 billion, a P/E ratio of 20.14, a P/E/G ratio of 3.35 and a beta of 1.11. Allegion has a 12 month low of $113.27 and a 12 month high of $156.10.

Allegion (NYSE:ALLE) last announced its quarterly earnings data on Thursday, October 24th. The scientific and technical instruments company reported $2.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.18. The company had revenue of $967.10 million for the quarter, compared to analysts’ expectations of $970.70 million. Allegion had a return on equity of 45.64% and a net margin of 15.36%. Allegion’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.94 earnings per share.

Institutional Trading of Allegion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALLE. Public Employees Retirement System of Ohio purchased a new position in shares of Allegion in the third quarter worth about $4,988,000. Renaissance Technologies LLC acquired a new stake in Allegion during the 2nd quarter valued at approximately $27,056,000. Qsemble Capital Management LP acquired a new stake in Allegion during the 3rd quarter valued at approximately $891,000. Nordea Investment Management AB boosted its holdings in shares of Allegion by 4.4% in the 4th quarter. Nordea Investment Management AB now owns 1,175,995 shares of the scientific and technical instruments company’s stock valued at $154,643,000 after acquiring an additional 49,176 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Allegion by 4.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,643 shares of the scientific and technical instruments company’s stock worth $1,260,000 after purchasing an additional 340 shares during the last quarter. Institutional investors and hedge funds own 92.21% of the company’s stock.

Insider Transactions at Allegion

In other Allegion news, SVP Robert C. Martens sold 8,035 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $144.92, for a total transaction of $1,164,432.20. Following the sale, the senior vice president now owns 7,104 shares of the company’s stock, valued at approximately $1,029,511.68. The trade was a 53.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John H. Stone purchased 7,500 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $140.70 per share, for a total transaction of $1,055,250.00. Following the purchase, the chief executive officer now directly owns 120,481 shares in the company, valued at $16,951,676.70. This represents a 6.64 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.33% of the company’s stock.

Allegion Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Tuesday, December 17th were given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 1.46%. The ex-dividend date of this dividend was Tuesday, December 17th. Allegion’s payout ratio is presently 29.49%.

About Allegion

Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door controls and systems and exit devices; locks, locksets, portable locks, and key systems and services; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors, accessories, and other.